Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rezolute Inc (NQ: RZLT )

4.520 +0.110 (+2.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rezolute Inc

< Previous 1 2 Next >
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceeds 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
Via Investor Brand Network
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in the Jefferies Global Healthcare Conference
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
From Rezolute, Inc.
Via GlobeNewswire
3 Stocks Insiders Are Buying That Analysts Love
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits. 
Via MarketBeat
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Plans to report topline data mid-second quarter 2024 
From Rezolute, Inc.
Via GlobeNewswire
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday... 
Via Newsfile
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports First Quarter Fiscal 2024 Results
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences in September
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare... 
Via Newsfile
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
From Rezolute, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.